Cargando…

Bipolar Disorder Pills in Perspective: Questions From Peer Review

I recently performed a peer review of a manuscript submitted for consideration for publication in the Journal of Managed Care Pharmacy (JMCP) on the subject of the total costs of care for patients with bipolar disorder treated with divalproex versus one of 3 atypical antipsychotics; 2 different clas...

Descripción completa

Detalles Bibliográficos
Autor principal: Barbuto, John P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438297/
https://www.ncbi.nlm.nih.gov/pubmed/15667236
http://dx.doi.org/10.18553/jmcp.2005.11.1.88
_version_ 1785092760201592832
author Barbuto, John P.
author_facet Barbuto, John P.
author_sort Barbuto, John P.
collection PubMed
description I recently performed a peer review of a manuscript submitted for consideration for publication in the Journal of Managed Care Pharmacy (JMCP) on the subject of the total costs of care for patients with bipolar disorder treated with divalproex versus one of 3 atypical antipsychotics; 2 different classes of medications were involved. In this regard, a point arose that divalproex treats mania but not depression in the condition singularly labeled as bipolar disorder. So, pitting the 2 classes against one another may not be appropriate unless one can argue that both classes treat the same problem. To a neurologist, the question is: What is the actual defect?
format Online
Article
Text
id pubmed-10438297
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-104382972023-08-21 Bipolar Disorder Pills in Perspective: Questions From Peer Review Barbuto, John P. J Manag Care Pharm Editorials I recently performed a peer review of a manuscript submitted for consideration for publication in the Journal of Managed Care Pharmacy (JMCP) on the subject of the total costs of care for patients with bipolar disorder treated with divalproex versus one of 3 atypical antipsychotics; 2 different classes of medications were involved. In this regard, a point arose that divalproex treats mania but not depression in the condition singularly labeled as bipolar disorder. So, pitting the 2 classes against one another may not be appropriate unless one can argue that both classes treat the same problem. To a neurologist, the question is: What is the actual defect? Academy of Managed Care Pharmacy 2005-01 /pmc/articles/PMC10438297/ /pubmed/15667236 http://dx.doi.org/10.18553/jmcp.2005.11.1.88 Text en Copyright © 2005, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Editorials
Barbuto, John P.
Bipolar Disorder Pills in Perspective: Questions From Peer Review
title Bipolar Disorder Pills in Perspective: Questions From Peer Review
title_full Bipolar Disorder Pills in Perspective: Questions From Peer Review
title_fullStr Bipolar Disorder Pills in Perspective: Questions From Peer Review
title_full_unstemmed Bipolar Disorder Pills in Perspective: Questions From Peer Review
title_short Bipolar Disorder Pills in Perspective: Questions From Peer Review
title_sort bipolar disorder pills in perspective: questions from peer review
topic Editorials
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438297/
https://www.ncbi.nlm.nih.gov/pubmed/15667236
http://dx.doi.org/10.18553/jmcp.2005.11.1.88
work_keys_str_mv AT barbutojohnp bipolardisorderpillsinperspectivequestionsfrompeerreview